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http://dx.doi.org/10Advances in the design of targeted therapies for the treatment of chronic myeloid leukemia
(CML) have transformed the prognosis for patients diagnosed with this disease. However,
leukemic stem cell persistence, drug intolerance, drug resistance, and advanced-phase disease
represent unmet clinical needs demanding the attention of CML investigators worldwide. The
availability of appropriate preclinical models is essential to efficiently translate findings from
the bench to the clinic. Here we review the current approaches taken to preclinical work in the
CML field, including examples of commonly used in vivo models and recent successes from
systems biology-based methodologies. Copyright  2016 ISEH - International Society for
Experimental Hematology. Published by Elsevier Inc.Chronic myeloid leukemia (CML) is a myeloproliferative Imatinib, approved by the Food and Drug Administra-
disorder of hematopoietic stem cell (HSC) origin caused
by the t(9;22) chromosomal translocation. Fusion of part
of the breakpoint cluster region (BCR) on chromosome
22 with the Abelson murine leukemia viral oncogene ho-
molog 1 (ABL) tyrosine kinase of chromosome 9 results
in formation of the Philadelphia (Ph) chromosome and
expression of the BCR-ABL fusion gene. The consequent
BCR-ABL protein generated is a constitutively active tyro-
sine kinase that can influence a number of major signaling
pathways involved in cell survival, proliferation, adhesion,
and differentiation. Clinically this presents as an expansion
of myeloid cells and an accumulation of differentiating
granulocytic precursors and differentiated effector cells,
with increased peripheral granulocytosis, splenomegaly,
thrombocytosis, and anemia. The majority of patients
tend to present with chronic phase disease (CP), which,
without therapeutic intervention, then proceeds through to
an accelerated phase (AP) and ultimately to blast crisis
(BC) over approximately 3 to 5 years (Fig. 1). The initial
dependence of CML on the expression of BCR-ABL has
led to the development of a number of ABL tyrosine kinase
inhibitors (TKIs), with such TKIs now representing the
front-line therapy for CML patients.o: Tessa L. Holyoake, Paul O’Gorman Leukaemia
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.1016/j.exphem.2016.11.005tion (FDA) in 2001, was the first TKI brought to the market
and approved for use in CML patients. By attaching closely
to the ATP binding site of BCR-ABL, this first-generation
TKI stabilizes the inactive conformation of BCR-ABL,
thus inhibiting its constitutive tyrosine kinase activity. Sub-
sequent second-generation TKIs have since been developed
to combat the problem of imatinib resistance, including da-
satinib, bosutinib, and nilotinib, and all are now approved
as first-line treatments for newly diagnosed CML patients,
with the exception of bosutinib, which tends to be pre-
scribed only when imatinib, dasatinib, and nilotinib are
not viable options. However, whether because of side ef-
fects, noncompliance, or TKI resistance, TKIs fail a signif-
icant proportion of patients, meaning that the development
of new therapies for treatment of CML is still a priority.
There are therefore still a number of areas of unmet clinical
need in the CML field that require attention, and so to effi-
ciently translate findings from the laboratory to patients, it
is essential to have effective preclinical models in place that
are predictive of performance in the clinic.In vitro models
Immortalized hematopoietic cell lines
Hematopoietic cell lines expressing the Ph chromosome pro-
vide a basic system in which to assess the molecular effectsmatology. Published by Elsevier Inc.
Figure 1. CML disease progression. The majority of CML patients are diagnosed in the chronic phase, which will progress through the accelerated phase to
blast crisis if untreated. Each phase can be characterized by the number of immature cells (blasts) found in the BM. Expression of BCR-ABL activates a
number of signaling pathways, resulting in increased proliferation and decreased apoptosis in the myeloid compartment. Secondary genetic and molecular
abnormalities lead to an accumulation of mutations and genomic instability, resulting in progression to blast crisis and poor patient prognosis.
14 C.J. Clarke and T.L. Holyoake/ Experimental Hematology 2017;47:13–23and responses of a CML-like cell (Table 1). Offering a contin-
uous source of reproducible cellular material and being
amenable to an exhaustive number of in vitro assays, immor-
talized cell lines are frequently used as an initial high-
throughput tool to validate potential therapeutic targets and
screen drug candidates. High-throughput screens (HTS)
have been instrumental in the development of CML therapies,
with the work that led to the discovery of imatinib stemming
from HTS-identified kinase inhibitors [1]. The ease withTable 1. Commercially available immortalized CML cell linesa
Cell line Cell type BCR-ABL status
K-562 CML in BC e14-a2 (b3-a2)
KU-812 CML in myeloid BC e14-a2 (b3-a2)
Bv-173 B-Cell precursor leukemia e13-a2 (b2-a2)
EM-2/EM-3 CML in BC e14-a2 (b3-a2)
NALM-1 CML in BC e13-a2 (b2-a2)
KCL-22 CML in BC e13-a2 (b2-a2)
LAMA-84 CML in BC e14-a2 (b3-a2)
JK-1 CML in BC e13-a2 (b2-a2)
MEG-01 CML in megakaryocytic BC e13-a2 (b2-a2)
JURL-MK1/MK-2 CML in BC e14-a2 (b3-a2)
KYO-1 CML in BC e13-a2 (b2-a2)
MEG-A2 CML e14-a2 (b3-a2)
MOLM-1 CML e13-a2 (b2-a2)
MOLM-6 CML in BC e13-a2 (b2-a2)
TK-6 CML e14-a2 (b3-a2)
BC 5 blast crisis; BM 5 bone marrow; CML 5 chronic myeloid leukemia.
aCML cell lines commercially available from DSMZ, including details of their d
confirmed by reverse transcription polymerase chain reaction (www.dsmz.de).which cell lines can be manipulated also enables their utiliza-
tion in a variety of ways, including genomewide RNA inter-
ference screens to identify TKI-resistant genes [2], and
reporter gene assays to provide further information regarding
the specificity of signaling pathways involved [3]. Further-
more, techniques that involve use of multiple constructs,
such as optimization of short interfering RNA/small
hairpin RNA-based approaches, would not be possible in
limited amounts of primary patient material, and so use ofDerivation
Pleural effusion of a 53-year-old woman with CML in terminal BC
(SPI-801 and SPI-802 derived from this line)
Peripheral blood of a 38-year-old male patient in BC of CML
Peripheral blood of a 45-year-old man with CML in blast crisis
Sister cell lines established from the BM of a 5-year-old Caucasian
girl in second relapse after BM transplant
Peripheral blood of a 3-year-old girl with CML
Pleural effusion of a 32-year-old woman with CML
Peripheral blood of a 29-year-old woman with CML after onset of
myeloid-megakaryocytic BC (LAMA-87 derived from this line)
Biopsy material of shoulder tumor from 62-year-old man with CML
in erythroid blast crisis
BM of a 55-year-old man with CML in megakaryocytic BC
Sister cell lines established from peripheral blood of a 73-year-old
man with CML in BC
Peripheral blood of a 22-year-old man with CML in myeloid BC
Peripheral blood of a 24-year-old man with CML in megakaryoblastic
crisis after chemotherapy
BM of a 41-year-old man with CML in BC
Peripheral blood of a 44-year-old man with CML in BC
Pleural effusion of a 30-year-old man with CML in T-cell lineage BC
after BM transplantation
erivation and which variant of the BCR-ABL fusion gene they express, as
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However, immortalized cell lines are often derived from pa-
tients in BC and, so, frequently contain further mutations in
addition to expression of the BCR-ABL fusion product.
Excessive culture in the hands of different research groups
can also mean that the same cell line in different laboratories
may ultimately become genetically distinct, and results gener-
ated in such systems are not necessarily indicative of in vivo
responses. Nevertheless, immortalized hematopoietic cell
lines are frequently used in early-stage projects to form the
basis of subsequent preclinical work, and gene expression
analysis of 40 hematologic cell lines revealed that the vast
majority of cell lines do indeed cluster according to clinical
and molecular subtype based on their gene expression profile
[4], indicating that they do, to a certain extent, retain the
appropriate pathways of interest. An initial review of CML-
derived cell lines indicated early support for the hypothesis
that the Ph translocation is not restricted to lineage-
committed progenitor cells [5], and ABL-specific TKIs are
consistently effective against human CML and Phþ cell lines
in vitro because of their dependence on BCR-ABL for prolif-
eration and survival [6,7]. Subsequent studies in BCR-ABL-
expressing cells also predicted that continuous suppression
of BCR-ABL would be necessary for clinical benefit in
CML [8], and therefore, although data generated in immortal-
ized hematopoietic cell lines should always be treated with
caution, their utility should not be underestimated.
Primary patient CML cells
The use of primary patient samples, comparing CML cells
with normal hematopoietic progenitors, is an essential
component of the preclinical CML package, combiningTable 2. Methods commonly used to assess hematopoietic stem cell cultures
Assay Principle
Colony-forming cell To study the proliferation and
differentiation pattern of
hematopoietic progenitors by
their ability to form colonies in
a semisolid medium
Long-term culture initiating cell Quantification of primitive
hematopoietic progenitors
Capable of initiating and
sustaining myelopoiesis for
several weeks in vitro through
co-culture methodology
Flow cytometry Passage of cells through a laser to
allow the detection of their
optical and fluorescence
characteristics
Competitive repopulation Assessment of the ability of
HSCs to serially transplant in
immunocompromised mice
HSC 5 hematopoietic stem cell.the relevance of variable patient biology with in vitro assays
to understand the molecular basis of disease and to indicate
responses to potential therapies. Because primary material
cannot be manipulated to the same extent as immortalized
cells, the assays amenable for use in such samples are some-
what more limited than those applied in immortalized cell
lines. However, there are still a large number of approaches
available for use in primary samples that can provide a
wealth of information, including colony-forming cell and
long-term culture-initiating cell assays, in addition to flow
cytometry, cell cycle and apoptosis, Western blot, immuno-
fluorescence, and polymerase chain reaction approaches
(Table 2). Improvements across ‘‘omics’’ approaches mean
that these powerful techniques are also now possible on
smaller amounts of starting material, even down to the
single-cell level in some instances, with such platforms
opening up a number of possibilities in understanding de-
regulated networks in disease and drug treatment [9,10].
Biobanks of such patient samples are an invaluable
source to researchers, and cells are often processed, banked,
and used as defined cell populations, such as CD34þ and
CD34þCD38 sorted cells, with CD34þ enrichment being
used as a bare minimum to deplete the mature granulated
cells that are numerous in CML and, when present, cause
technical issues on degranulation during freeze–thaw. Use
of dual-fluorescence in situ hybridization (D-FISH) for
BCR-ABL is also necessary to distinguish normal versus
CML cells that coexist within the same stem cell compart-
ment of patients. Once CML CD34þ cells of interest are
isolated and placed in liquid culture with appropriate sup-
porting growth factors, difficulties encountered in vitro
include expanding the primitive cells of interest and theirPros Cons
Rapid method for identifying
progenitor cells
Cells of interest can be harvested
from individual colonies for
further analysis
Not able to detect more primitive
HSCs
Able to detect primitive HSCs Time consuming
Variation in procedure and
stromal cells can influence
outcome
Rapid method
Able to identify and isolate HSCs
and other cells of interest
Surface antigen detection is not
functional data
In vivo system with more
appropriate microenvironment
Secondary transplants possible as
a true measure of long- term
multilineage engraftment
Time consuming
Expensive
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mature when cultured [11]. Despite these technical limita-
tions, the use of primary CML material in vitro has been
instrumental in developing our understanding of CML cells
and their response to therapy. Although TKI resistance is a
well-recognized limitation in the treatment of CML
[12,13], leukemic stem cell (LSC) persistence also under-
lies our current inability to cure the disease. While, in the
absence of drug resistance, TKIs are effective against the
majority of CD34þCD38þ and CD34þCD38 cells in
CML patients [14,15], more primitive LSCs are much
less susceptible to the apoptosis induced by TKI treatment,
with their persistence maintaining disease [16–19]. Data
derived from human primary samples therefore indicate
that LSC survival is not dependent on BCR-ABL kinase ac-
tivity [20,21], and curative therapies in CML will thus have
to target additional pathways.
The comparison of primary cell populations derived from
normal donors versus CML patients has implicated a large
number of molecular pathways in LSC survival, with a num-
ber of these pathways being reviewed concisely elsewhere
[22,23]. Combined approaches targeting BCR-ABL and
additional targets in such pathways have thus been investi-
gated in CML CD34þ cells. These include studies assessing
the effects of the Janus kinase 2 inhibitors, which indicated
that reduced activity of the Janus kinase 2/signal transducer
and activator of transcription 5 pathway, in combination
with BCR-ABL inhibition by nilotinib, was able to increase
apoptosis of CML stem/progenitor cells, both in vitro and
in vivo [24–27]. Furthermore, activation of peroxisome pro-
liferator activated receptor gamma by the anti-diabetic drug
pioglitazone was also able to work synergistically with TKI
to deplete CML LSCs through decreasing expression of
signal transducer and activator of transcription 5 and its
downstream targets [28]. Altered transforming growth factorTable 3. Key discoveries made in CML mouse models and examples of some o
mouse models
Model Key d
Retroviral CML-like myeloproliferative syndrome can be i
transplanted into recipients
Transforming ability of BCR-ABL results from
Lineage-restricted target cells and mutational eve
for full malignant transformation
SCLtTA/BCR-ABL Expression of BCR-ABL specifically in hemato
disease
Leukemic phenotype reversed and re-induced b
LSCs are not oncogene addicted
BCR-ABL expression induces differentiation and
Disease is transplantable by LSKs, but more sev
unfractionated BM
Xenograft Correlation between engraftment in model and
Identification of specific subpopulations of prim
initiating activity
Dynamic role of the BM microenvironment
BC 5 blast crisis; BM 5 bone marrow; CML 5 chronic myeloid leukemia; LSbeta-forkhead box signaling has also been found in LSCs
following TKI exposure [29], with transforming growth fac-
tor beta inhibitors being effective in reducing colony forma-
tion in vitro [30], while a number of studies have implicated
the Hedgehog pathway in LSC persistence [31–33] with
consequent use of a smoothened (SMO) inhibitor, in combi-
nation with TKI, reducing CD34þCP-CML cell engraftment
in vivo [33]. At the epigenetic level, use of histone deacety-
lase inhibitors, in combination with TKI, have been shown
to successfully target quiescent LSCs [34], while enhancer
of zeste homolog 2 (EZH2) and H3K27me3 reprogramming
have also been found to be important for LSC survival, with
consequent use of EZH2 inhibitors in combination with TKI
also providing a promising therapeutic means of eradicating
LSCs [10]. The contribution of cellular processes, in addition
to specific signaling pathways, to LSC survival has also been
probed, including targeting autophagy and lipid metabolism
to induce cell death in Phþ primary CML stem cells [35–37].
And so, use of primary CML patient cells in vitro has been
essential in understanding which dual targeting approaches
may be successful going forward to the clinic.In vivo models
Although the use of in vitro techniques is a necessary pre-
requisite to all projects that progress to generate therapeutic
opportunities, in vivo models have the major advantage of
providing a more relevant microenvironment, recapitulating
interactions between different cell types under more appro-
priate physiologic conditions. There are currently three
commonly used mouse models applied in CML research
(Table 3), with each having its own advantages and caveats,
and each being appropriate in its own right depending on
the hypothesis being tested.f the key findings resulting from use of the three commonly used CML
iscovery Reference
nduced in mice when BCR-ABL-infected BM is [38–40]
constitutive tyrosine kinase activity [38–40]
nts additional to BCR-ABL expression are required [41]
poietic stem/progenitor cells induces CML-like [42]
y removing and re-introducing tetracycline; thus [42]
decreases self-renewal capacity of LSK population [43]
ere phenotype is observed after transplantation of [44]
disease state of patient material [45,46]
ary CML cells capable of long-term leukemia- [47–49]
[50,51]
C 5 leukemic stem cell; LSK 5 LinSca-1þc-kitþ.
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The murine retroviral model involves infection of
5-fluorouracil (5-FU) treated mouse bone marrow cells with
retrovirus encoding BCR-ABL, followed by transplantation
of transduced cells into irradiated syngeneic recipients [38–
40] (Fig. 2A). Recipients develop hematologic malignancies,
including a myeloproliferative CML-like disease resembling
CP human CML. Although these studies established that
BCR-ABL in such a system can cause myeloproliferative dis-
ease inmice, in these initial models more than one type of dis-
ease developed, whereas the leukemic phenotype observed
was also dependent on how donor mice were conditioned,
suggesting that the target cell in which BCR-ABL was ex-
pressed, and additional mutations in those cells, was impor-
tant in determining the disease burden [41]. Furthermore,
using the original published methods, not all recipients devel-
oped CML-like disease with a consistent latency. As a conse-
quence, a number of variants of the retroviral model,
including use of modified retroviral constructs, different viral
packaging systems, and alternative viral infection methods,
have since been described in the literature, resulting in a
frequently used model with faithful development of CML-
like syndrome in 100% of recipients 2–4 weeks post trans-
plantation [52,53]. The rapid onset of disease in this model
means that it is much more aggressive than the typical pro-A
B
C
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Figure 2. Schematic representation of the three mouse models of CML. The thre
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and transplanted into immunocompromised recipient mice.gression of CML in human patients; however, in an experi-
mental setup, this can also have it advantages, allowing
efficient feedback to evaluate the therapeutic effects of agents
tested in vivo. The retroviral method is also an effective
method to monitor the effects of co-expression or deletion
of other genes of interest, and their variants, with data gener-
ated in this model revealing that expression of interferon reg-
ulatory factors, for example, can act in a tumor suppressor role
to regulate proliferation of normal and leukemic hematopoiet-
ic cells, with consequent overexpression of such factors inhib-
iting myeloproliferative disorder [54]. Recent work has also
indicated that the scaffolding adaptor protein GRB2-associ-
ated binding protein 2 is required for BCR-ABL-induced
leukemogenesis [55], and that IkB kinase-dependent activa-
tion of NF-kB can also contribute to Phþ leukemias [56],
whereas others have used the samemodel to illustrate that tar-
geting methyltransferases, such as protein arginine methyl-
transferase 5 (PMRT5), can eliminate LSCs [57], thus
identifying additional potential therapeutic targets of interest.
Furthermore, it is also an ideal system in which to understand
the effect of mutant variants of BCR-ABL, with studies indi-
cating that although T315I and Y253H mutations of BCR-
ABL confer resistance to imatinib, they do not provide a
growth advantage in the absence of TKI [58]. The effects of
therapeutics can thus be tested in a setting that compares method Downstream analysis
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treatment with a HSP90 inhibitor indicating that HSP90 could
be a therapeutic target for CML induced by either WT or
T315I BCR-ABL [52,59]. Triple-gene-expression systems
can also be effectively used in the retroviral model, designing
constructs to simultaneously express BCR-ABL, Cre recom-
binase (Cre), and GFP to enable assessment of BCR-ABL in
GFP-selected cells for a conditional Cre-induced knockout of
interest. In such cases, deletion of the tumor suppressor gene
phosphatase and tensin homolog (PTEN) was found to accel-
erate the development of CML, as recipient mice receiving
cells transduced from bone marrow (BM) of Ptenfl/fl mice
with BCR-ABL-Cre-GFP retrovirus developed CML at a
faster rate than those receiving cells transduced with the cor-
responding BCR-ABL-GFP control retrovirus, while overex-
pression of PTEN consequently delayed CML development
[52]. Gene expression can therefore be manipulated with
ease in the retroviral transduction/transplantation model,
and so this murine approach is an effective means of assessing
the effects of specific targets of interest, their interaction with
BCR-ABL, and their responses to targeted therapies.
SCLtTA/BCR-ABL transgenic model
In the SCLtTA/BCR-ABL transgenic mouse model of
leukemogenesis the expression of P210 BCR-ABL is
regulated by a tetracycline-controlled transactivator (tTA)
under the control of the murine stem cell leukaemia gene
3’ enhancer (SCL), specifically driving expression of
BCR-ABL in the stem and progenitor cells of the hemato-
poietic system when tetracycline is removed from the drink-
ing water [42] (Fig. 2B). Clinical characteristics following
BCR-ABL expression in this model include neutrophilia,
leukocytosis, and invasion of myeloid cells into multiple or-
gans, including the liver, lungs, and lymph nodes, thus also
conferring a CML-like disease to the mice following BCR-
ABL expression. Although survival following BCR-ABL
expression varies, on average, from 4 to 10 weeks, the
model does result in a consistent expansion of the HSC
and myeloid compartments of the BM and an increase in
the number of progenitor cells in the spleen. As opposed
to the fast and dramatic onset of disease in the retroviral
model, this system has a natural progression that is more
similar to that of human CML and, thus, may provide a
more physiologically relevant model for studying the events
that initially follow BCR-ABL expression [42]. Further-
more, the phenotype is also transplantable in sublethally
irradiated syngeneic recipients, via both LinSca-1þc-kitþ
(LSK) cells and unfractionated BM, with transplant of un-
fractionated BM generating a more severe disease pheno-
type, presumably because of the presence of supporting
cells. Leukemic spleen cells are also capable of transplant-
ing disease, with expression of BCR-ABL in such cells hav-
ing cell-autonomous effects that consequently affect their
engraftment potential and response to TKI [44]. Studies
based on this model have reinforced the understandingthat the inhibition of BCR-ABL in vivo does not eliminate
the LSKs that maintain disease, and have also indicated that
BCR-ABL expression induces differentiation and decreases
the self-renewal capacity of the LSK population [21,44].
Gene expression profiling in the LSK population from
BCR-ABLþ and control mice revealed that BCR-ABL
expression induced an increase in expression of genes
involved in proliferation and myeloid differentiation,
whereas genes involved in self-renewal were downregulated
[43]. The contribution of genomic instability to disease pro-
gression has also been investigated, with elevated levels of
reactive oxygen species-induced DNA damage being found
in LSCs, which was consequently able to generate a number
of clinically relevant mutations in BCR-ABL and additional
tumor-promoting factors [60]. The SCLtTA/BCR-ABL
model has also been used to explore the role of the micro-
environment in CML development, with studies indicating
that leukemic myeloid cells can remodel the endosteal
BM niche into an environment that impairs normal hemato-
poiesis and promotes leukemic progression [61], and that
specific cytokines produced by leukemic cells can influence
the BM microenvironment to provide favorable conditions
for CML LSC growth [62]. This transgenic system is thus
a suitable model in which to assess the effects of therapies
on long-term HSC (LT-HSCs) in an appropriate in vivo
microenvironment.
Further derivations of the SCLtTA/BCR-ABL model
have also been generated. To recapitulate progression to
BC in an unbiased in vivo setting, Giotopoulos et al com-
bined the SCLtTA/BCR-ABL double transgenic model
with a transposon-based insertional mutagenesis system to
generate a murine model of CML progression [63]. The
addition of a transposition element to this model,
mimicking the additional chromosomal instability and
mutagenesis occurring in BC, resulted in a change in termi-
nal kinetics of the disease and an increase in myeloid leuke-
mogenesis. Analysis of common insertion sites revealed
disruption of a number of genes with known associations
with CML progression, particularly genes involved in tran-
scriptional regulation of the stem cell compartment, and
progression to BC in the model displayed gene expression
profiles comparable to those of human BC. The BC-
associated signature included increased expression of c-
Myc and its targets, suggesting that activation of this
pathway is important during BC progression. This was
further reinforced by the ability of I-BET (an inhibitor
effective against bromodomain and extraterminal [BET]
proteins, which are critical in mediating Myc transcription),
to decrease clonogenic growth in both the mouse model and
patient samples. However, it was also interesting to note
that the comparison of insertion sites between CML-BC
mice and mice harboring only the transposition element
differed, indicating that BCR-ABL may influence muta-
tional selection pressure. Thus, in addition to identifying
and testing potential therapeutic targets of interest,
19C.J. Clarke and T.L. Holyoake/ Experimental Hematology 2017;47:13–23evolution of existing disease models can also provide addi-
tional information on the molecular progression of disease
processes.
Xenograft model
In the xenotransplant model of CML human malignant cells
are engrafted into immunocompromised mice, with the sub-
sequent frequency of LSCs, and their long-term Phþ engraft-
ment ability, then being assessed. Although a number of
different mouse strains are amenable for use, including
NOD.Cg-Prkdcscid/IL2rgtm1Wjl/SzJ (NSG) and NOD.Cg-
PrkdcscidIl2rgtm1Sug/JicTac (NOG) mice, the common theme
among them is their immunodeficient status, which facili-
tates engraftment of human cells [64,65]. Additional strains
are now becoming commercially available with the purpose
of facilitating increased engraftment of human cells, with
examples including the NOD.Cg-PrkdcscidIl2rgtm1WjlTg
(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ (NSG-SGM3/
NSGS) [66] and Rag2tm1.1FlvCsf1tm1(CSF1)FlvCsf2/
Il3tm1.1(CSF2,IL3)FlvThpotm1.1(TPO)FlvIl2rgtm1.1FlvTg(SIRPA)
1Flv/J strains (MISTRG, with a MITRG strain also available
that does not include the BAC-transgene encoding human
SIRPa) [67], all of which transgenically express human
cytokines with the aim of improving human cell engraftment,
and the NOD.Cg-KitW-41JTyrþPrkdcscidIl2rgtm1Wjl/ThomJ
(NBSGW) strain, where a Kit mutation is proposed to facilitate
the engraftment of human hematopoietic cells without the stan-
dard requirement of irradiation [68]. As appreciation of the role
of the microenvironment in leukemia development grows [50],
implantation of scaffolds into mice is also now being used to
mimic the human BM niche, with ceramic scaffolds coated
in human mesenchymal stromal cells (MSCs) generating a
more human-like BM microenvironment to consequently
improve the self-renewal properties of stem cells [51,69].
The xenograft model of assessing human cell popula-
tions in immunocompromised mice is frequently used to
study hematologic malignancies, as specific subpopulations
of primary CML cells are capable of long-term leukemia-
initiating activity [47–49]. The engraftment potential of
CD34þ cells is commonly tested in sublethally irradiated
recipients 12 to 16 weeks following transplant to ensure
monitoring of the effects on LT-HSCs only, using D-FISH
on remaining cells to distinguish the specificity of drug ef-
fects on Phþ and Ph populations [70] (Fig. 2C). The level
of engraftment obtained has been found to correlate with
the phase of the disease the patient material is sampled
from, with BC cells engrafting at higher rates than those
in CP [45,46]. However, such long-term studies can be
limiting in terms of time and affordability, and so alterna-
tive approaches have also been employed, including exam-
ples of engraftment for only 1 week followed by 2 weeks of
drug treatment [71] and ex vivo treatment of cells prior to
transplant [9,26]. Furthermore, mice engrafted with CML
samples do not display the clinical signs of disease associ-
ated with other murine CML models, and interpatientvariability in CML samples and low levels of engraftment
add to the model’s limitations. However, despite these tech-
nical caveats, the xenograft model of CML remains a gold
standard in vivo contribution to preclinical studies. Recent
work that illustrated the importance of EZH2 and
H3K27me3 reprogramming in LSC survival was able to
show the effectiveness of combining an EZH2 inhibitor
with nilotinib on PhþCD45þCD34þCD38 cells from the
BM of NSG xenografted mice, being the first published
study of CML CP to illustrate efficacy in such a primitive
cell population in vivo [10]. The alternative mouse strains
now becoming available to researchers in the CML field
should make assessment of such primitive populations
even more feasible and conducted as standard, and so,
going forward, these models are likely to facilitate assess-
ment of the most primitive populations of stem cells
responsible for maintaining disease, will reduce animal
numbers used, and may also allow development of a clini-
cally characterized leukemia, and thus will provide crucial
preclinical information required to generate confidence in
therapies progressing toward clinical trials.Biomarkers
The transition of potential therapies from first-in-human
studies to phase III registration is associated with high rates
of attrition. In addition to improvements in preclinical
models, the development of appropriate biomarkers, to
enable both correct patient stratification and predict drug
response, is necessary to improve the progression of drugs
through clinical trials and beyond. In CML, the presence of
the Phþ chromosome and levels of BCR-ABL transcript
can act as chromosomal and molecular markers of disease,
respectively, and hematologic, cytogenetic, and molecular
responses can thus be monitored in CML patients at defined
time points according to principles proposed by European
Leukemia Net (ELN) and the National Comprehensive
Cancer Network (NCCN) [72,73]. However, prognostic
biomarkers that correlate with clinical outcome, and predic-
tive markers of drug resistance, are required to further
inform therapeutic strategies. Gene expression profiling
through use of microarray has been used in an attempt to
identify biomarkers that are predictive of TKI failure,
with analysis of CML CD34þ cells revealing that genes
associated with adhesion are consistently upregulated in
TKI nonresponders [74]. Assessment of gene expression
changes associated with progression from AP to BC also
identified specific gene expression signatures and upregu-
lated signaling pathways, such as the Wnt/b-catenin
pathway, with disease progression [75], with such studies
providing valuable information to indicate which combina-
torial drug choices are most likely to be successful in spe-
cific patients. Target-specific biomarkers have been used as
commonplace to assess drug response, including assess-
ment of levels of p53, p21, MDM2, Ki-67, and blood
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inhibitors in liposarcoma [76] and c-Myc mRNA/protein
levels and assessment of expression of bromodomain
4-dependent genes following use of BET inhibitors in xeno-
graft models of Burkitt’s lymphoma [77]. Although not
tested in CML models themselves, the known deregulation
of such pathways in CML suggests these biomarkers may
also have utility in CML-based models. However, global
RNA sequencing following drug treatment in vitro or
in vivo can also provide a means of nonbiased screening
to interrogate drug action and, thus, can generate a wealth
of knowledge for biomarker development. Use of such
methods has indicated that drugs designed to stabilize the
p53 pathway increase expression of genes associated with
apoptosis, whereas inhibitors targeting c-Myc activity can
induce transcriptional responses associated with differenti-
ation, in both TKI responder and nonresponder populations
[9]. With increased publication of ‘‘big data’’-based ap-
proaches, projects such as Stemformatics are now providing
a platform for researchers to access well-curated biological
sequence data [78], and so improvements and increased
accessibility to nonbiased ‘‘omic’’ approaches will there-
fore not only improve patient stratification, but will also
facilitate prognostic and predictive biomarker identification
to inform rationale for treatment selection.Systems biology
Integrating computational approaches to model complex
biological systems, systems biology is a powerful technique
that can be used to enhance our understanding of the
complexity of the multiple molecular mechanisms impli-
cated in cancer. Integrating systems-level analysis across
multiple cancer types has identified common mechanisms
that drive carcinogenesis, including aberrant metabolomics
and defective DNA repair [79,80]. Other studies have indi-
cated how systematic analysis of proteomic data can predict
drug response and therefore guide therapy selection,
including computational approaches in AML, which have
predicted sensitivity or resistance to phosphoinositide 3 ki-
nase/AKT inhibition using phosphoproteomic data [81].
The systems biology approach was also recently used to
powerful effect in CML, where Abraham, Hopcroft, and
colleagues used network analysis of proteomic and tran-
scriptomic data to identify p53 and c-Myc as key hubs
that mediate networks to maintain LSCs in CML [9].
Although the identification of p53 and c-Myc as drivers
of a cancer phenotype is not a novel concept, with previ-
ously described work in the retroviral model being one of
many studies to implicate c-Myc in CML progression
[63], and studies inhibiting SIRT1 indicating that activation
of p53 can enhance elimination of CML LSCs in combina-
tion with imatinib mesylate [82], it was the combination of
‘‘omic’’ approaches in normal and CML cells with network
analysis that enabled identification of c-Myc and p53 as keyregulators of the CML phenotype, despite these targets not
being identified as differentially regulated components at
the proteomic and transcriptomic level themselves [9].
Combining drug treatments in normal and CML LSCs
in vitro with in vivo xenograft NSG and syngeneic
SCLtTA/BCR-ABL transgenic models, the authors effec-
tively used numerous preclinical models to illustrate that
dual targeting of p53 and c-Myc in CML can synergistically
kill and eliminate BCR-ABLþ LSCs through increased
apoptosis and differentiation. Furthermore, by using drugs
already undergoing testing in human clinical trials
(Clinicaltrials.gov Identifiers: NCT01773408 and
NCT02158858) and ensuring the appropriate networks are
still present in TKI nonresponder patients, this package of
work combining in vitro, in vivo, and systems-based ap-
proaches effectively discovered combinatorial targets that
provide promise for future CML therapies.Conclusions
To effectively translate exploratory findings into successful
therapies, robust and reproducible preclinical models that
are predictive of patient response are needed. As in other
therapeutic areas, CML research has been advanced
through the use of numerous models, ranging from immor-
talized cell lines to primary patient samples and a variety of
murine models. Initially thought of as a classic example of
how a genetic abnormality can cause cancer, CML treat-
ment was revolutionized by the advent of TKIs, leading
the way in the development of targeted therapies. However,
in addition to detection of disease persistence in the clinic,
detailed investigations in the described preclinical models
have been instrumental in understanding the molecular
mechanisms that facilitate the maintenance of CML.
Although individual preclinical approaches are often
selected based on the hypothesis to be tested, novel combi-
natorial approaches are able to identify important compo-
nents of therapeutic interest that might have otherwise
been missed using targeted experimental methodologies.
Whilst new preclinical models of CML will no doubt be
developed in the coming years, to succeed in efficiently
progressing therapies through clinical trials and to the pa-
tient, it will be the combination and package of preclinical
models assembled that will be important in providing the
understanding to predict which therapies will be most effec-
tive in curing CML.Acknowledgments
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